vimarsana.com

Metabolomics Bioinformatics Tools Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Metabolomics Market to Expand at a CAGR of ~13% Assessment for the Driving Factors, Size, Revenue, Segments, Expansion, Demand, and Opportunities During 2023-2033 by Newsmantraa | Online Free Press release news distribution

Global Metabolomics Market Trends, Strategies, And Opportunities In The Metabolomics Market 2021-2030

Metabolomics Global Market Report 2021: COVID-19 Growth And Change To 2030 The Business Research Company’s Metabolomics Global Market Report 2021: COVID-19 Growth And Change To 2030 LONDON, GREATER LONDON , UK, April 14, 2021 /EINPresswire.com/ According to the new market research report ‘Metabolomics Global Market Report 2021: COVID-19 Growth And Change To 2030’ published by The Business Research Company, the metabolomics market is expected to reach $3.6 billion in 2025 at a CAGR of 12.3%. Increasing prevalence rate of cancer drives the metabolomics market growth. Metabolomics screens the potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to measure the cancer drug responsiveness aiding early diagnosis.

Global Metabolomics Market (2020 to 2025) - Biomarker Development Presents Opportunities

Share this article Share this article ResearchAndMarkets.com s offering. The global metabolomics market size is projected to reach USD 4.1 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 13.4% during the forecast period. The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine, and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry. However, issues related to data examination & data processing in metabolomics and the high cost of tools and instruments are likely to restrain the market growth to a certain extent.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.